Immunic highlights lead asset's promise in multiple sclerosis at ECTRIMS CongressProactive Investors • Wednesday
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple SclerosisPRNewsWire • Wednesday
Immunic reports first patient enrolled in investigator-sponsored post-COVID syndrome trialProactive Investors • 09/04/24
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID SyndromePRNewsWire • 09/04/24
Immunic to highlight lead asset's promise at upcoming Multiple Sclerosis R&D DayProactive Investors • 08/28/24
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in SeptemberPRNewsWire • 08/28/24
Immunic strengthens leadership team as MS trials advance toward key milestonesProactive Investors • 08/08/24
Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatePRNewsWire • 08/08/24
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate UpdatePRNewsWire • 08/01/24
Immunic chief scientific officer shares insights on innovative MS therapy - ICYMIProactive Investors • 07/27/24
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona SkerjanecPRNewsWire • 07/24/24
Immunic appoints ex Novartis and Biogen exec as new COO to lead vidofludimus calcium launchProactive Investors • 07/09/24
Immunic advances ‘potentially groundbreaking' MS therapy vidofludimus calcium during Q1Proactive Investors • 05/08/24
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate UpdatePRNewsWire • 05/08/24
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate UpdatePRNewsWire • 05/01/24
Immunic publishes extended data from Phase 2 MS trial in peer-reviewed journalProactive Investors • 04/30/24
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & NeuroinflammationPRNewsWire • 04/30/24